Table 4.
mTOR Target.
| Agent | Trial | Phase | Number | Patient | Therapy | Dosing | Results a vs b |
|---|---|---|---|---|---|---|---|
| Everolimus | Zhu et al. (2011) [128] | I/II | 28 | Prior therapy | a. Everolimus (n = 28) | Everolimus 5 or 10 mg daily | OS: 8.4 months; PFS: 3.8 months; ORR: 4%; DCR: 44% |
| EVOLVE-1 (2014) [129] | III | 546 | Failed sorafenib | a. Everolimus (n = 362); b. Placebo (n = 184) |
Everolimus 7.5 mg daily | OS: 7.6 months vs. 7.3 months; TTP: 3.0 months vs. 2.6 months, HR 0.93 DCR: 56.1% vs. 45.1%, p = 0.01 |
OS: median overall survival; PFS: median progression free survival; TTP: median time to progression; ORR: objective response rate; DCR: disease control rate.